MusclePharm Corp (MSLP) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
4721 IRONTON STREET DENVER, CO 80239 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2022 MRQ | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 1,223 | 2,003 | 1,532 | 6,228 | 4,943 | 7,081 | |||
| Cash and cash equivalents | 1,223 | 2,003 | 1,532 | 6,228 | 4,943 | 7,081 | |||
| Receivables | 6,388 | 7,488 | 4,807 | 16,668 | 13,353 | 22,003 | |||
| Inventory, net of allowances, customer advances and progress billings | 1,830 | 1,032 | 4,720 | 6,484 | 8,568 | 12,549 | |||
| Inventory | 1,830 | 1,032 | 4,720 | 6,484 | 8,568 | 12,549 | |||
| Prepaid expense | 89 | ||||||||
| Other undisclosed current assets | 1,526 | 1,341 | 1,104 | 993 | 1,930 | 5,646 | |||
| Total current assets: | 10,967 | 11,864 | 12,163 | 30,462 | 28,794 | 47,279 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 203 | 474 | 1,175 | ✕ | ✕ | ✕ | |||
| Property, plant and equipment | 5 | 13 | 216 | 1,822 | 3,243 | 6,693 | |||
| Long-term investments and receivables | 977 | ||||||||
| Long-term investments | 977 | ||||||||
| Intangible assets, net (including goodwill) | 35 | 356 | 676 | 1,317 | 1,638 | 8,652 | |||
| Intangible assets, net (excluding goodwill) | 35 | 356 | 676 | 1,317 | 1,638 | 8,652 | |||
| Other noncurrent assets | 295 | 310 | 225 | 421 | 180 | ||||
| Total noncurrent assets: | 243 | 1,138 | 2,377 | 3,364 | 5,302 | 16,502 | |||
| TOTAL ASSETS: | 11,210 | 13,002 | 14,540 | 33,826 | 34,096 | 63,781 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 23,922 | 14,725 | 30,983 | 19,503 | 18,676 | 52,178 | |||
| Accounts payable | 17,980 | 14,719 | 26,178 | 11,742 | 9,625 | 39,652 | |||
| Accrued liabilities | 5,942 | 6 | 4,805 | 7,761 | 9,051 | 12,526 | |||
| Debt | 17,021 | 10,881 | 10,184 | ||||||
| Restructuring reserve | 595 | 614 | 9,140 | ||||||
| Other undisclosed current liabilities | 132 | 6,401 | 374 | 8,385 | 19,146 | 5,970 | |||
| Total current liabilities: | 41,075 | 32,007 | 41,541 | 28,483 | 38,436 | 67,288 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 2,326 | 1,308 | 723 | 16,815 | 332 | 6,282 | |||
| Long-term debt, excluding current maturities | 2,326 | 965 | 16,669 | 332 | 5,952 | ||||
| Capital lease obligations | ✕ | ✕ | ✕ | ✕ | 146 | 330 | |||
| Liabilities, other than long-term debt | 120 | 208 | 279 | ||||||
| Restructuring reserve | 120 | 208 | 279 | ||||||
| Operating lease, liability | 343 | 723 | ✕ | ✕ | ✕ | ||||
| Other undisclosed noncurrent liabilities | 3,763 | (495) | 942 | ||||||
| Total noncurrent liabilities: | 2,326 | 5,414 | 951 | 17,877 | 540 | 6,561 | |||
| Total liabilities: | 43,401 | 37,421 | 42,492 | 46,360 | 38,976 | 73,849 | |||
| Equity | |||||||||
| Equity, attributable to parent | (32,191) | (24,419) | (27,952) | (12,534) | (4,880) | (10,068) | |||
| Common stock | 32 | 32 | 31 | 14 | 14 | 14 | |||
| Treasury stock, value | (10,039) | (10,039) | (10,039) | (10,039) | (10,039) | (10,039) | |||
| Additional paid in capital | 183,355 | 178,261 | 177,914 | 159,608 | 156,301 | 147,646 | |||
| Accumulated other comprehensive loss | (150) | (162) | (172) | ||||||
| Accumulated deficit | (205,539) | (192,673) | (195,858) | (161,967) | (150,994) | (147,517) | |||
| Total equity: | (32,191) | (24,419) | (27,952) | (12,534) | (4,880) | (10,068) | |||
| TOTAL LIABILITIES AND EQUITY: | 11,210 | 13,002 | 14,540 | 33,826 | 34,096 | 63,781 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2022 TTM | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 50,042 | 64,440 | 79,667 | 102,155 | 132,499 | 166,858 | ||
| Revenue, net | ✕ | ✕ | ✕ | ✕ | 102,155 | 132,499 | 166,858 | |
| Cost of revenue (Cost of Goods and Services Sold) | (44,671) | (44,831) | (70,979) | (71,710) | (88,026) | (109,927) | ||
| Gross profit: | 5,371 | 19,609 | 8,688 | 30,445 | 44,473 | 56,931 | ||
| Operating expenses | (14,284) | (17,007) | (23,795) | (37,634) | (53,131) | (106,878) | ||
| Operating income (loss): | (8,913) | 2,602 | (15,107) | (7,189) | (8,658) | (49,947) | ||
| Nonoperating income (expense) | (28) | 147 | (4,883) | (1,712) | (1,754) | |||
| Investment income, nonoperating | 383 | (837) | ||||||
| Gain (loss), foreign currency transaction, before tax | (28) | (236) | 26 | |||||
| Debt instrument, convertible, beneficial conversion feature | 601 | 52 | ||||||
| Other nonoperating expense | (4,072) | (2,313) | (1,806) | |||||
| Interest and debt expense | (5,460) | 659 | (3,609) | (3,215) | (702) | |||
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | (95) | (272) | 4,457 | 7,913 | (52) | |||
| Income (loss) from continuing operations before equity method investments, income taxes: | (14,401) | 3,166 | (18,841) | (10,830) | (3,159) | (51,753) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 1,527 | (1) | ||||||
| Income (loss) from continuing operations before income taxes: | (12,874) | 3,166 | (18,841) | (10,831) | (3,159) | (51,753) | ||
| Income tax expense (benefit) | 8 | 19 | (86) | 108 | (318) | (105) | ||
| Income (loss) from continuing operations: | (12,866) | 3,185 | (18,927) | (10,723) | (3,477) | (51,858) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | (12,866) | 3,185 | (18,927) | (10,723) | (3,477) | (51,858) | |
| Net income (loss): | (12,866) | 3,185 | (18,927) | (10,723) | (3,477) | (51,858) | ||
| Other undisclosed net loss attributable to parent | (250) | |||||||
| Net income (loss) available to common stockholders, diluted: | (12,866) | 3,185 | (18,927) | (10,973) | (3,477) | (51,858) | ||
Comprehensive Income ($ in thousands)
| 3/31/2022 TTM | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (12,866) | 3,185 | (18,927) | (10,723) | (3,477) | (51,858) | ||
| Comprehensive income (loss): | (12,866) | 3,185 | (18,927) | (10,723) | (3,477) | (51,858) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (184) | (238) | 10 | (106) | ||||
| Comprehensive income (loss), net of tax, attributable to parent: | (12,866) | 3,185 | (19,111) | (10,961) | (3,467) | (51,964) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.